Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis

Table 2

Performances of biomarkers in lung cancer diagnosis.

Biomarkers	Sensitivity	Specificity	PPV	NPV	AUC (95% CI)
CYFR21	0.735	0.732	0.824	0.619	0.806 (0.743-0.859)
CEA	0.654	0.827	0.817	0.669	0.797 (0.741-0.845)
NSE	0.444	0.757	0.757	0.444	0.597 (0.525-0.665)
SCC	0.192	0.848	0.862	0.426	0.579 (0.511-0.645)
CA125	0.400	0.879	0.833	0.493	0.661 (0.598-0.720)
CA15-3	0.371	0.951	0.920	0.500	0.703 (0.642-0.759)
CA199	0.190	0.915	0.786	0.478	0.503 (0.439-0.567)
CA50	0.063	0.988	0.889	0.411	0.572 (0.494-0.651)
CA242	0.095	0.871	0.522	0.394	0.570 (0.492-0.649)
CA724	0.157	0.941	0.800	0.428	0.583 (0.507-0.660)
The panel 1	0.894	0.619	0.724	0.839	0.854 (0.791-0.904)
The panel 2	0.955	0.576	0.716	0.919	0.875 (0.815-0.921)
The panel 3	0.598	0.730	0.725	0.604	0.776 (0.705-0.837)
The panel 4	0.955	0.525	0.692	0.912	0.884 (0.825-0.928)

PPV: positive predictive value; NPV: negative predictive value; Pane l = CYFR21, CEA, NSE, and SCC; panel 2 = CYFR21, CEA, NSE, SCC, CA125, and CA15-3; panel 3 = CA125, CA15-3, CA19-9, CA50, CA242, and CA724; panel 4 = CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724.